Full-Time

Medical Director

Attovia

Attovia

51-200 employees

Clinical-stage biopharma developing biparatopic nanobodies

Compensation Overview

$280k - $315k/yr

San Carlos, CA, USA

In Person

In-office at least 4 days per week; relocation to San Carlos, California if required.

MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Pharmacology
Data Analysis

Get referred to Attovia

See people who can refer or advise you

Requirements
  • MD with a minimum of 4 years of clinical drug development. Active medical license preferred.
  • Ability to work in a fast-paced, small biotech environment.
  • Ability to interpret medical safety data independently without additional oversight.
  • Exceptional written and verbal communication skills as evidenced by publications and platform presentations at scientific meetings.
  • Proven track record of successful design and implementation of clinical trials. Prior experience in early-stage drug development (Phase 1 to 2) strongly preferred.
  • Demonstrated leadership presence, with the ability to foster relationships with key opinion leaders, study investigators, and academic collaborators.
  • Therapeutic experience in immune-mediated diseases. Expertise in inflammatory bowel disease is preferred but not required.
  • Strong analytical skills with the ability to interpret complex data sets and make informed decisions.
  • Familiarity with the general principles of pharmacology/toxicology as it relates to first-in-human studies and early drug development.
  • Proactive personality, positive/solution-oriented mindset, careful attention to detail, adaptability to rapidly changing environment, and high ethical standards.
  • Willingness to travel intermittently for conferences, investigator meetings, and advisory boards.
  • Willingness to work in-office at least 4 days per week and relocate if necessary.
Responsibilities
  • Lead cross-functional study teams in the design, implementation, analysis, and interpretation of clinical trials. Ensure that project deliverables are accomplished on time and within budget.
  • Assist in authoring clinical-regulatory documents, including study protocols, investigator brochures, IND/CTAs, informed consents, clinical study reports, procedure manuals, statistical analysis plans, and briefing documents for health authorities.
  • Act as the medical monitor for Attovia clinical trials. Conduct regular medical safety data reviews. Identify, manage, and communicate potential safety signals.
  • Prepare and deliver presentations and other scientific communications for internal and external stakeholders, including clinical advisors and study investigators.
  • Engage with key opinion leaders to gain medical insights, inform clinical development plans, and build awareness and enthusiasm for Attovia’s programs.
  • Organize and conduct clinical/scientific advisory board meetings as needed.
  • Partner with Clinical Science and Clinical Operations to identify and build strong professional relationships with study investigators.
  • Partner with Clinical Operations to identify, select, and manage CROs, study sites, and clinical vendors.
  • Serve as the medical knowledge expert in target indication(s), develop target product profiles, and contribute to clinical and regulatory strategy.
  • Partner with Project Management to ensure that clinical activities, timelines, and budgets are aligned with overall corporate goals.

Preparing company summary.

Company Size

51-200

Company Stage

IPO

Headquarters

Fremont, California

Founded

2023

Get referred to Attovia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Attovia priced its August 4, 2026 IPO at $17, raising $289 million.
  • The IPO plus cash supports operations into 2029, funding multiple clinical milestones.
  • Board additions on July 15, 2026 and strong demand signal institutional backing after listing.

What critics are saying

  • ATTO-1310 still faces human proof-of-concept risk; failure kills the platform story by 2027.
  • ATTO-2306 collides with Sanofi and Regeneron’s Dupixent, squeezing differentiation and pricing power.
  • Post-IPO expectations into 2029 depend on successful Phase 2 data; misses force dilution.

What makes Attovia unique

  • ATTOBODY’s biparatopic nanobodies attack two sites, targeting GPCRs and cytokines other biologics miss.
  • Attovia’s pipeline spans pruritus, atopic dermatitis, and IBD, not a single-disease story.
  • The Alamar worldwide license gives Attovia exclusive platform rights and proprietary engineering leverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

10%
wallstreet:online AG
Aug 5th, 2026
Attovia Therapeutics prices upsized $289M IPO at $17 per share

Attovia Therapeutics, a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases, priced its upsized initial public offering at $17.00 per share. The San Carlos-based company will sell 17,000,000 shares, generating gross proceeds of $289.0 million before underwriting costs and expenses. Attovia has also granted underwriters a 30-day option to purchase up to 2,550,000 additional shares at the offering price. The company's common stock is expected to begin trading on the Nasdaq Global Market on 5 August 2026 under the ticker symbol "ATTO", with the offering closing on 6 August 2026. Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers, whilst LifeSci Capital acts as passive book-running manager.

AInvest Fintech Inc.
Jul 14th, 2026
Goldman Sachs and venBio hold 5%+ stakes in Attovia after $105M Series B

Attovia Therapeutics has disclosed that Venbio Global Strategic Fund IV and Goldman Sachs-affiliated entities each hold 5% or greater stakes in the company. This follows Attovia's oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives with participation from venBio and other investors. Since launching in June 2023, Attovia has raised $165 million in total. The Series B proceeds will advance lead programmes ATTO-1310 and ATTO-002 through initial clinical readouts and further develop its ATTOBODY platform. Goldman Sachs Alternatives appointed Colin Walsh to Attovia's board of directors. VenBio has been a consistent investor since Attovia's inception. The increased ownership reflects investor confidence in Attovia's pipeline and proprietary platform for developing bi-specific therapeutics targeting immune-mediated diseases.

FinSMEs
Apr 16th, 2025
Attovia Therapeutics Raises $90M in Series C Financing

Attovia Therapeutics, a San Carlos, CA-based privately-held, clinical-stage biopharma company, raised $90M in Series C funding

Greenville Business Magazine
Apr 15th, 2025
Attovia secures $90M for ATTOBODY programs

Attovia Therapeutics announced a $90 million Series C financing led by Deep Track Capital, with participation from new and existing investors. The funds will advance clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and expand their pipeline of multi-specific therapeutic candidates. Rebecca Luse from Deep Track Capital will join the Board of Directors. The financing supports Attovia's goal of achieving clinical proof-of-concept for its lead assets.

BioSpace
May 9th, 2024
Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies

The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another for immune-mediated diseases.